Skip to main content

Table 2 Clinical, cost and utility inputs

From: Cost-utility analysis of percutaneous mitral valve repair in inoperable patients with functional mitral regurgitation in German settings

Variable Base Case Value Range Distribution for probabilistic sensitivity analysis Reference
Characteristics of patients’ population     
Age, years 62 50–80 Normal [13]
    (SD =12)  
Male gender, % 77 0–100 Beta  
Proportion of patients with severe MR at baseline in both arms 0.639 0.511–0.766 Beta  
    (α = 23; β = 13)  
Proportion of patients with severe MR between 1 and 5 months in PMVR arm 0.35 0.28–0.42 Beta  
    (α = 12; β = 22)  
Proportion of patients with severe MR from 6 months and onwards in PMVR arm 0.258 0.206–0.309 Beta  
    (α = 8; β = 23)  
Effectiveness data and transition probabilities     
Probability of peri-procedural mortality 0.019 0.01–0.03 Beta [13]
    (α = 1; β = 52)  
Probability of myocardial infarction, which leads to PCI 0.04 0.02–0.06 Beta  
    (α = 2; β = 51)  
Probability of vessel perforation 0.02 0–0.03 Beta  
    (α = 1; β = 52)  
Probability of unsuccessful percutaneous annuloplasty 0.32 0.05–0.40 Beta  
    (α = 17; β = 36)  
Probability of arrhythmia 0.04 0.02–0.06 Beta Assumption
    (α = 2; β = 51)  
Six-month probability of excess mortality for NYHA class II 0.04 0.02–0.06 Beta [22]
    (α = 4; β = 96)  
Six-month probability of excess mortality for NYHA class III 0.07 0.035–0.105 Beta  
    (α = 7; β = 93)  
Six-month probability of excess mortality for NYHA class IV 0.28 0.14–0.42 Beta  
    (α = 28; β = 72)  
Monthly probability of hospitalization for NYHA class I 0.015 0.008–0.023 Beta [21]
    (α = 1.5; β = 98.5)  
Monthly probability of hospitalization for NYHA class II 0.024 0.012–0.036 Beta  
    (α = 2.4; β = 97.6)  
Monthly probability of hospitalization for NYHA class III 0.024 0.012–0.036 Beta  
    (α = 2.4; β = 97.6)  
Monthly probability of hospitalization for NYHA class IV 0.154 0.077–0.231 Beta  
    (α = 15.4; β = 84.6)  
Relative risk for all-cause mortality with present severe MR 1.5 1.1–1.9 Log-normal (SElog = 0.26) [23]
Relative risk for hospitalization due to HF with present severe MR 1.7 1.3–2.1 Log-normal (SElog = 0.33)  
Resource utilization and cost data     
Cost of Carillon device, € 18,000 12,600–23,400 - Cardiac Dimensions, Inc.
Cost of PMVR placement procedure, € 4844 3391–6297 - G-DRG code F19C
Cost of treatment of vessel perforation after PMVR placement, € 1998 1399–2597 -  
Percentage of patients being hospitalized with stay in intensive care unit 7.2 % - Dirichlet [27]
Percentage of patients being hospitalized with stay in coronary care unit 25.6 % -   
Percentage of patients being hospitalized with CABG performed 0.3 % -   
Percentage of patients being hospitalized with PTCA performed 0.2 % -   
Percentage of patients being hospitalized with heart transplantation performed 2.6 % -   
Percentage of patients being hospitalized with no procedure performed 62.3 % -   
Cost of hospitalization with stay in intensive care unit, € 5004 3503–6506 - G-DRG code F62A 2013
Cost of hospitalization with stay in coronary care unit, € 5004 3503–6506 - G-DRG code F62A 2013
Cost of hospitalization with CABG performed, € 15,056 10,539–19,573 - G-DRG code F06E
Cost of hospitalization with PTCA performed, € 3793 2655–4931 - G-DRG code F56B plus ZE101
Cost of hospitalization with heart transplantation performed, € 86,337 60,436–112,239 - G-DRG code A05B 2013
Cost of hospitalization with no procedure performed, € 2740 1918–3562 - G-DRG code F62B 2013
Annual cost of routine management of heart failure in NYHA class I, € 495 258–1031 Gamma [26]
    (α = 1;λ = 516)  
Annual cost of routine management of heart failure in NYHA class II, € 874 455–1821 Gamma  
    (α = 1;λ = 910)  
Annual cost of routine management of heart failure in NYHA class III, € 864 450–1800 Gamma  
    (α = 1;λ = 900)  
Annual cost of routine management of heart failure in NYHA class IV, € 929 484–1935 Gamma  
    (α = 1;λ = 967)  
Utility data     
Utility for NYHA I class 0.815 0.652–0.978 Beta [27]
    (α = 395; β = 90)  
Utility for NYHA II class 0.720 0.576–0.864 Beta  
    (α = 662; β = 257)  
Utility for NYHA III class 0.590 0.472–0.708 Beta  
    (α = 360; β = 250)  
Utility for NYHA IV class 0.508 0.406–0.609 Beta (α = 52; β = 50)  
Decrement for percutaneous annuloplasty procedure 0.043 0.034–0.051 Beta [29]
    (α = 96; β = 2129)  
  1. SD, standard deviation; MR, mitral regurgitation; PMVR, percutaneous mitral valve repair; NYHA, New York Heart Association